Indeed, although recently the combination of standard chemotherapy with bevacizumab has been proposed as the best therapeutic option for BRAF-mutated advanced CRCs [34], the prognosis of these patients is still dismal compared to other molecular subtypes of colon cancers [10, 27]. The gene discussed is BRAF; the disease is malignant colon neoplasm.